8-K: Klotho Neurosciences Secures $11 Million, Achieves Debt-Free Status, and Nears Nasdaq Compliance

Klotho Neurosciences, Inc. announced it raised over $11 million through warrant exercises, extinguished all outstanding debt, and believes it now meets Nasdaq's stockholders' equity requirements.

Summary

• Klotho Neurosciences, Inc. successfully raised approximately $11 million in funding through the exercise of outstanding warrants during the period from June 8, 2025, through June 13, 2025.
• The company utilized $3.1 million of the newly raised funds to fully extinguish all outstanding debt, resulting in a debt-free balance sheet.
• As a direct result of the warrant exercises, Klotho Neurosciences believes its stockholders' equity now exceeds the minimum $2.5 million Nasdaq requirement for continued listing.
• The company intends to formally notify Nasdaq of its compliance status to seek a determination regarding its regained compliance with all applicable listing requirements.

Sentiment

Score: 8

Explanation: The announcement is overwhelmingly positive, addressing critical financial stability, debt elimination, and Nasdaq compliance issues. These are significant achievements for a publicly traded company, especially one in the capital-intensive biogenetics sector. The only minor uncertainty is Nasdaq's final determination, but the company's position is strong.

Positives

• Successfully raised over $11 million in capital through the exercise of existing warrants, demonstrating investor confidence and providing significant liquidity.
• Achieved a debt-free balance sheet by extinguishing all $3.1 million of outstanding debt, significantly improving financial health and reducing financial risk.
• The company believes it has regained compliance with Nasdaq's minimum $2.5 million stockholders' equity requirement, addressing a critical listing concern and potentially preventing delisting.

Negatives

• There is no assurance that Nasdaq will definitively determine that the company has regained compliance with its continued listing standards, despite the company's current belief.

Risks

• The company's belief of regaining Nasdaq compliance is not a guarantee; Nasdaq must make its own determination, and there is no assurance of a positive outcome.
• Forward-looking statements are subject to various risks and uncertainties, including the company's potential inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections.
• Changes in the regulatory or competitive environment in which Klotho Neurosciences operates could materially affect its future events and financial results.

Future Outlook

The company's future commercial operations are subject to various risks and uncertainties, including its ability to implement business plans, identify and realize additional opportunities, or meet financial projections, as well as changes in the regulatory or competitive environment. Klotho Neurosciences intends to notify Nasdaq of its compliance status for a determination regarding continued listing.

Management Comments

• Klotho believes it now exceeds the stockholders equity thresholds required to remain in compliance with NASDAQ listing requirements.
• The Company intends to notify Nasdaq of its compliance status so that Nasdaq can make a determination as to whether the Company has regained compliance with all applicable requirements for continued listing.

Industry Context

Klotho Neurosciences operates in the highly specialized and capital-intensive biogenetics sector, focusing on developing innovative cell and gene therapies for neurodegenerative and age-related disorders. This successful funding round and debt elimination significantly strengthen the company's financial foundation, which is crucial for advancing its proprietary Klotho gene-based therapeutic programs and maintaining its competitive position within the biopharmaceutical industry.

Comparison to Industry Standards

• NA. The document does not provide specific comparable companies, projects, or results to assess the financial outcomes against global benchmarks or industry peers.

Stakeholder Impact

• **Shareholders**: The successful capital raise and debt extinguishment significantly improve the company's financial health and reduce financial risk, potentially leading to increased investor confidence and share price stability. The belief of regaining Nasdaq compliance is crucial for continued listing and liquidity.
• **Creditors**: All outstanding debt has been extinguished, meaning previous creditors have been fully paid off, eliminating the company's financial obligations to them.
• **Employees**: Improved financial stability and a debt-free balance sheet may provide greater job security and resources for ongoing research, development, and operational activities.

Next Steps

• The company intends to notify Nasdaq of its compliance status.
• Nasdaq will then make a determination regarding whether Klotho Neurosciences has regained compliance with all applicable requirements for continued listing.

Key Dates

Recommendation

Keywords

Biogenetics, Neurosciences, Cell therapy, Gene therapy, Klotho gene, NASDAQ compliance, Warrant exercise, Debt extinguishment, ALS, Alzheimer's disease, Parkinson's disease, Biopharmaceutical, SEC filing, 8-K